December 02, 2008
Mylan Pharmaceuticals has entered into a deal with Novartis to market letrozole 2.5 mg tablets, a generic version of Novartis's breast cancer product Femara. Letrozole tablets posted U.S. sales of approximately $470 million for the 12 month period ending Sept. 30, 2008, according to a Mylan statement.
Titan Pharmaceuticals, a manufacturer focused primarily on the development and commercialization of Probuphine, a treatment for opiate addiction, has reduced its workforce by 40%. Further staff reductions are anticipated in the next several weeks, a company statement said.